Pfizer and BioNTech submitted an application to the US Food and Drug Administration for emergency use authorization of an additional booster dose of their Covid-19 vaccine for adults 65 and older who have gotten a booster dose of any of the authorized or approved vaccine.
The submission is based on two data sets from Israel. In a news release, the company said that both data sets showed evidence that an additional mRNA booster increases immunogenicity and lowers rates of confirmed infections and severe illness.
